Vaccine Hopes Rise After Latest Data From Pfizer

View Transcript
November 18, 2020
Hopes of a path back to normalcy in the U.S. were raised this week, thanks to the latest news from Pfizer. The pharmaceutical giant says its final analysis of its Phase 3 vaccine trial suggests a stunning 95% efficacy rate. The company could seek FDA emergency use authorization for the vaccine within days. We discuss the latest developments with Professor Peter Pitts, founder of the Center for Medicine in the Public Interest, and a former FDA Associate Commissioner.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.